PHARMExcel celebrates 13 successful years!
This month PHARMExcel reaches yet another milestone as it celebrates 13 years of successful business.
PHARMExcel are delighted to announce their future collaboration with DIOSynVax to support the delivery of their forthcoming clinical trial program.
This programme, (supported by CEPI funding), will provide the infrastructure to help design and select the lead antigen through proof-of-concept preclinical studies, progressing to initial clinical development through Phase I/II studies. DIOSynVax aim to establish clinical proof of concept for a novel vaccine candidate with the potential to provide broad protection against Sarbecovirus, Merbecovirus, Embecovirus and Nobecovirus.
Adopting a New Agile Approach to CRO Clinical Trial Management
Following its reputation of excellence in delivering investigator-led studies, PHARMExcel was selected to manage the Covid-19 vaccine booster study.
New EU Clinical Trial Regulation
The new EU clinical trial regulation (CTR) is set to revolutionise clinical trial processes across Europe impacting all European Member states and organisations wanting to run clinical trials across these regions. How can organisations prepare for the change and set themselves up successfully with a new CTR programme?
Yvanne Enever, Founder/CEO reflects on 2021
We are pleased to say that 2021 has seen PHARMExcel busier than ever. From delivering the Worlds’ first Booster Vaccine clinical trial leading to the shaping of UK Government policy, to welcoming new, key staff appointments and undertaking several charity events for Macmillan Cancer Support, Team PHARMExcel showed dedication to the cause. As we complete…
PHARMExcel delighted to be the selected U.K. CRO delivering this pivotal clinical trial alongside colleagues at University Southampton, Cambridge and DIOSynVax.
PHARMExcel are pleased to announce the publication of the safety and immunogenicity data from the UK’s Covboost trial.
Covid booster jabs will begin to be offered across the UK from next week based on JCVI decisions following COVBoost clinical trial data.
